L-Citrulline monohydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-Citrulline monohydrochloride
• 英文别名: 2-amino-5-(carbamoylamino)pentanoic acid;hydrochloride
• 化学式: C6H14ClN3O3
• 分子量: 211.65
• InChiKey: RSQCFPZQHNPAAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.73
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  118
• 氢给体数：
  5
• 氢受体数：
  4

文献信息

• CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER
  申请人：Pierre Fabre Medicament

  公开号：US20170112943A1

  公开（公告）日：2017-04-27

  The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.

  本发明涉及一种抗体药物偶联物或包含该偶联物的药物组合物。从一方面来说，该发明涉及一种抗体药物偶联物（ADC），包括一种由曲妥珠单抗或其生物类似物组成的抗体，所述抗体与至少一种由单甲基奥瑞他汀F衍生物组成的药物偶联。该发明还包括一种治疗癌症的方法，包括向受试者施用有效量的所述抗体药物偶联物或包含该偶联物的组合物。
• [EN] COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER<br/>[FR] COMPOSITION POUR LE TRAITEMENT D'UN CANCER EXPRIMANT IGF-1R
  申请人：PF MEDICAMENT

  公开号：WO2017072196A1

  公开（公告）日：2017-05-04

  The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention reates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

  本发明涉及一种用于治疗表达IGF-IR的癌症的方法，以及用于所述治疗的组合物和试剂盒。从一方面来说，发明涉及第一抗体用于确定癌症的IGF-IR状态和第二抗体作为ADC用于治疗所述癌症的联合使用。
• [EN] IMPROVED METHOD OF SYNTHESIS AND PURIFICATION OF CITRULLINE<br/>[FR] PROCÉDÉ AMÉLIORÉ DE SYNTHÈSE ET DE PURIFICATION DE LA CITRULLINE
  申请人：ASKLEPION PHARMACEUTICALS LLC

  公开号：WO2020247853A1

  公开（公告）日：2020-12-10

  This invention provides for synthesis of citrulline from a transition metal complex of ornithine using cyanate to derivatize the terminal amino group of ornithine. The invention also provides improved methods for purification of citrulline produced by reaction of cyanate with ornithine via the steps of reprecipitation of copper complex of citrulline, removal of the complexing metal by sulfide precipitation, activated carbon adsorption and antisolvent crystallization.

  本发明提供了一种从鸟氨酸的过渡金属配合物中使用氰酸盐对鸟氨酸的末端氨基基团进行衍生化来合成精氨酸的方法。本发明还提供了改进的精氨酸纯化方法，通过再沉淀精氨酸铜配合物，通过硫化物沉淀去除络合金属，活性炭吸附和反溶剂结晶的步骤来制备氨基酸。
• KIT COMPRISING IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP3498301A1

  公开（公告）日：2019-06-19

  The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

  本发明涉及一种能够结合 IGF-1R 的抗体-药物-轭合物。从一个方面来说，本发明涉及一种抗体-药物-轭合物，它包括一种能够与 IGF-1R 结合的抗体，所述抗体与至少一种选自多拉他汀 10 和曙红的衍生物的药物结合。本发明还包括治疗癌症的方法和使用所述抗体-药物共轭物的方法。
• ANTI-B7H3 ANTIBODY-EXATECAN ANALOG CONJUGATE AND MEDICINAL USE THEREOF
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：EP3854816A1

  公开（公告）日：2021-07-28

  Disclosed by the present invention are an anti-B7H3 antibody-exatecan analog conjugate, a preparation method therefor and an anti-tumor medicinal use thereof.

  本发明公开了一种抗 B7H3 抗体-埃沙替康类似物共轭物、其制备方法及其抗肿瘤药物用途。